PMID- 21455420
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 43
IP  - 1
DP  - 2011 Feb
TI  - Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute 
      exacerbation of chronic bronchitis: A randomized, controlled trial.
PG  - 40-4
LID - 10.4103/0253-7613.75667 [doi]
AB  - OBJECTIVE: Acute exacerbation of chronic bronchitis (AECB) is a commonly 
      encountered problem and those suspected to be due to bacterial infections require 
      antibiotic therapy. This randomized, controlled trial was designed to evaluate 
      the effectiveness and safety of gemifloxacin, a new fluoroquinolone, versus 
      cefpodoxime, an oral third-generation cephalosporin, for the treatment of mild to 
      moderately severe cases of AECB. MATERIALS AND METHODS: Adult subjects diagnosed 
      with chronic bronchitis with clinical symptoms suggestive of an Anthonisen type 
      II acute exacerbation (any two of the following criteria - increased dyspnea, 
      cough, sputum purulence) were eligible and those fulfilling the subject selection 
      criteria were randomized to receive either gemifloxacin 320 mg once daily or 
      cefpodoxime 200 mg twice daily orally for 7 days. The primary outcome measure was 
      clinical success rate at day 14 visit and the secondary outcome measures were 
      changes in Clinical Global impression (CGI) scales and incidence of adverse 
      events (AEs). Fifty-two subjects were enrolled: 26 in gemifloxacin group and 24 
      in the other and 2 were lost to follow-up. RESULTS: The clinical success rates 
      were comparable (84.6% in gemifloxacin group versus 83.3% in cefpodoxime group) 
      and no statistically significant difference was observed between the groups. AEs 
      were mild, self-limiting and few (two in gemifloxacin and three in cefpodoxime 
      arm) and tolerability was also good. CONCLUSION: The results of this randomized, 
      single-blind trial demonstrated that a 7-day course of gemifloxacin is 
      therapeutically comparable to cefpodoxime in terms of both clinical effectiveness 
      and safety for the treatment of type II Anthonisen category AECB patients.
FAU - Chatterjee, S
AU  - Chatterjee S
AD  - Department of Pharmacology, Institute of Postgraduate Medical Education and 
      Research, Kolkata, India.
FAU - Biswas, T
AU  - Biswas T
FAU - Dutta, A
AU  - Dutta A
FAU - Sengupta, G
AU  - Sengupta G
FAU - Mitra, A
AU  - Mitra A
FAU - Kundu, S
AU  - Kundu S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
PMC - PMC3062119
OTO - NOTNLM
OT  - Acute exacerbation of chronic bronchitis
OT  - cefpodoxime
OT  - clinical trial
OT  - gemifloxacin
EDAT- 2011/04/02 06:00
MHDA- 2011/04/02 06:01
PMCR- 2011/02/01
CRDT- 2011/04/02 06:00
PHST- 2010/04/07 00:00 [received]
PHST- 2010/07/07 00:00 [revised]
PHST- 2010/10/21 00:00 [accepted]
PHST- 2011/04/02 06:00 [entrez]
PHST- 2011/04/02 06:00 [pubmed]
PHST- 2011/04/02 06:01 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - IJPharm-43-40 [pii]
AID - 10.4103/0253-7613.75667 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2011 Feb;43(1):40-4. doi: 10.4103/0253-7613.75667.